13D Filing: Baker Bros. Advisors and Bellicum Pharmaceuticals Inc (NASDAQ:BLCM)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

SCHEDULE 13D

Under the Securities Exchange Act of
1934

(Amendment No. 2)*

Bellicum Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, Par Value $0.01 Per Share

(Title of Class of Securities)

079481107

(CUSIP number)

 

Alexandra A. Toohey

Chief Financial Officer

Baker Bros. Advisors LP

667 Madison Avenue, 21^st Floor

New York, NY 10065

(212) 339-5690

(Name,
address and telephone number of person authorized to receive notices and communications)

March 23, 2017

(Date of event which requires filing of
this statement)

If the filing person has previously filed a statement on Schedule
13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e),
13d-1(f) or 13d-1(g), check the following box. x

(Continued on the following pages)

Note: Schedules filed in paper format shall include a
signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to
be sent.

*The remainder of this cover page shall be filled out for a
reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page
shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).

CUSIP No.  079481107

Page   2   of  9   Pages

1.	NAMES OF REPORTING PERSONS Baker Bros. Advisors LP
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) p (b) p
3.	SEC USE ONLY
4.	SOURCE OF FUNDS* OO
5.	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) o
6.	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7.	SOLE VOTING POWER 5,032,313
		8.	SHARED VOTING POWER: 0
		9.	SOLE DISPOSITIVE POWER: 5,032,313
		10.	SHARED DISPOSITIVE POWER: 0
11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 5,032,313
12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) p
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 15.3% (1)
14.	TYPE OF REPORTING PERSON (See Instructions) IA, PN

(1) Based on 32,905,565 shares of common stock that will be
outstanding following the Offering (as defined below) including 750,000 shares issued as part of the Underwriter’s (as defined
below) option reported in the Issuer’s Prospectus filed with the SEC on March 24, 2017.

CUSIP No.  079481107

Page   3   of  9   Pages

1.	NAMES OF REPORTING PERSONS Baker Bros. Advisors (GP) LLC
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) p (b) p
3.	SEC USE ONLY
4.	SOURCE OF FUNDS* OO
5.	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) o
6.	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7.	SOLE VOTING POWER 5,032,313
		8.	SHARED VOTING POWER: 0
		9.	SOLE DISPOSITIVE POWER: 5,032,313
		10.	SHARED DISPOSITIVE POWER: 0
11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 5,032,313
12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) p
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 15.3% (1)
14.	TYPE OF REPORTING PERSON (See Instructions) HC, OO

(1) Based on 32,905,565 shares of common stock that will be
outstanding following the Offering (as defined below) including 750,000 shares issued as part of the Underwriter’s (as defined
below) option reported in the Issuer’s Prospectus filed with the SEC on March 24, 2017.

CUSIP No.  079481107

Page   4   of  9   Pages

 

1.	NAMES OF REPORTING PERSONS Julian C. Baker
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) p (b) p
3.	SEC USE ONLY
4.	SOURCE OF FUNDS* OO
5.	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) o
6.	CITIZENSHIP OR PLACE OF ORGANIZATION United States
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7.	SOLE VOTING POWER: 5,032,313
		8.	SHARED VOTING POWER: 0
		9.	SOLE DISPOSITIVE POWER: 5,032,313
		10.	SHARED DISPOSITIVE POWER: 0
11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 5,032,313
12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) p
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 15.3% (1)
14.	TYPE OF REPORTING PERSON (See Instructions) IN, HC

(1) Based on 32,905,565 shares of common stock that will be
outstanding following the Offering (as defined below) including 750,000 shares issued as part of the Underwriter’s (as defined
below) option reported in the Issuer’s Prospectus filed with the SEC on March 24, 2017.

CUSIP No.  079481107

Page   5   of  9   Pages

 

1.	NAMES OF REPORTING PERSONS Felix J. Baker
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) p (b) p
3.	SEC USE ONLY
4.	SOURCE OF FUNDS* OO
5.	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) o
6.	CITIZENSHIP OR PLACE OF ORGANIZATION United States
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7.	SOLE VOTING POWER: 5,032,313
		8.	SHARED VOTING POWER: 0
		9.	SOLE DISPOSITIVE POWER: 5,032,313
		10.	SHARED DISPOSITIVE POWER: 0
11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 5,032,313
12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) p
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 15.3% (1)
14.	TYPE OF REPORTING PERSON (See Instructions) IN, HC

(1) Based on 32,905,565 shares of common stock that will be
outstanding following the Offering (as defined below) including 750,000 shares issued as part of the Underwriter’s (as defined
below) option reported in the Issuer’s Prospectus filed with the SEC on March 24, 2017.

 

Amendment No. 2 to Schedule 13D

 

This Amendment No. 2 to Schedule 13D amends and supplements
the previously filed Schedules 13D filed by Baker Bros. Advisors LP (the “Adviser”), Baker Bros. Advisors (GP), LLC
(the “Adviser GP”), Julian C. Baker and Felix J. Baker. Except as supplemented herein, such statements, as heretofore
amended and supplemented, remain in full force and effect.

The
Adviser GP is the sole general partner of the Adviser. Pursuant to the management agreements, as amended, among the Adviser,
Baker Brothers Life Sciences, L.P. (“Life Sciences”),
14159, L.P. (“14159”), and 667, L.P. (“667”, and together with Life Sciences and 14159, the “Funds”)
and their respective general partners relinquished to the Adviser all discretion and authority with respect to the investment and
voting power of the securities held by the Funds, and thus the Adviser has complete and unlimited discretion and authority with
respect to the Funds’ investments and voting power over investments.

Item 3. Source and Amount of Funds or Other Consideration.

 

Item 3 of Schedule 13D is supplemented and amended, as the case
may be, as follows:

The disclosure regarding the purchases in Item 4 below is incorporated
herein by reference.

Item 4. Purpose of the Transaction.

Item 4 of Schedule 13D is supplemented and superseded, as the
case may be, as follows:

This Amendment No. 2 is being filed to report the acquisition
of shares of Common Stock of Bellicum Pharmaceuticals, Inc. (the “Issuer”) in an Offering (defined below) and a change
in the percentage of beneficial ownership resulting from the Offering.

On March 23, 2017, the Issuer entered into an underwriting agreement
(the “Underwriting Agreement”) with Citigroup Global Markets and Jefferies LLC, as representatives of the several underwriters
listed on Schedule A thereto (the “Underwriters”), related to a public offering (the “Offering”) of 5,000,000
shares of the Issuer’s common stock at a price to the public of $12.00 per share. In addition, the Issuer granted the Underwriters
an option exercisable for 30 days from the date of the Underwriting Agreement to purchase, at the public offering price less any
underwriting discounts and commissions, up to an additional 750,000 shares of common stock to cover overallotments, if any. The
Offering is expected to close on March 29, 2017.

Pursuant to the Offering, on March 24, 2017, 667 and Life Sciences
purchased 15,489 and 151,177 shares of the Issuer’s common stock, respectively, at the offering price of $12.00 per share,
totaling 166,666 shares in the aggregate. Each of 667 and Life Sciences purchased the shares of the Issuer’s commons stock
with their working capital.

The Funds hold securities of the Issuer for investment purposes.
The Reporting Persons or their affiliates may purchase additional securities or dispose of securities in varying amounts and at
varying times depending upon the Reporting Persons’ continuing assessments of pertinent factors, including the availability
of shares of common stock of the Issuer (“Common Stock”) or other securities for purchase at particular price levels,
the business prospects of the Issuer, other business investment opportunities, economic conditions, stock market conditions, money
market conditions, the attitudes and actions of the board of directors and management of the Issuer, the availability and nature
of opportunities to dispose of shares of the Issuer and other plans and requirements of the particular entities. The Reporting
Persons may discuss items of mutual interest with the Issuer, which could include items in subparagraphs (a) through (j) of Item
4 of Schedule 13D.

Depending upon their assessments of the above factors, the Reporting
Persons or their affiliates may change their present intentions as stated above and they may assess whether to make suggestions
to the management of the Issuer regarding financing, and whether to acquire additional securities of the Issuer, including shares
of Common Stock (by means of open market purchases, privately negotiated purchases, or otherwise) or to dispose of some or all
of the securities of the Issuer, including shares of Common Stock, under their control.

Except as otherwise disclosed herein, at the present time, the
Reporting Persons do not have any plans or proposals with respect to any extraordinary corporate transaction involving the Issuer
including, without limitation, those matters described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

Item 5.

Interest in Securities of the Issuer.

(a) and (b) Items 7 through 11 and 13 of each
of the cover pages of this Amendment No. 2 are incorporated herein by reference. Set forth below is the aggregate number and percentage
of shares of Common Stock directly held, as of the date hereof, by each of the following based upon 32,905,565 shares of Common
Stock that will be outstanding following the Offering including 750,000 shares issued as part of the Underwriters option, as reported
in the Issuer’s Prospectus filed with the SEC on March 24, 2017. Such percentage figures were calculated in accordance with
Rule 13d-3 under the Securities Exchange Act of 1934, as amended.

		Number of
		Shares of
		Common Stock
		we own or have
		the right to
		acquire within 60				Percent of Class
Name		days				Outstanding
667, L.P.			434,760				1.3	%
Baker Brothers Life Sciences, L.P.			4,527,089				13.8	%
14159, L.P.			70,464				0.2	%
Total			5,032,313				15.3	%

The Adviser GP, Felix J. Baker and Julian C. Baker as principals
of the Adviser GP, and the Adviser may be deemed to be beneficial owners of securities of the Issuer directly held by the Funds,
and may be deemed to have the power to vote or direct the vote of and the power to dispose or direct the disposition of such securities.

The Reporting Persons disclaim beneficial ownership of the securities
of the Issuer held by each of the Funds, and this Amendment No. 2 shall not be deemed an admission that the Reporting Persons are
the beneficial owners of such securities for purposes of Section 13(d) or for any other purpose, except to the extent that any
such Reporting Persons actually exercises voting or dispositive power with respect to such securities.

(c) The information set forth in Item 4 is hereby incorporated
by reference into this Item 5(c). Except as disclosed herein, none of the Reporting Persons or their affiliates has effected any
other transactions in securities of the Issuer during the past 60 days.

(d) Certain securities of the Issuer are held directly by 667,
a limited partnership the sole general partner of which is Baker Biotech Capital, L.P., a limited partnership the sole general
partner of which is Baker Biotech Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling members of Baker Biotech
Capital (GP), LLC.

Certain securities of the Issuer are held directly by Life Sciences,
a limited partnership the sole general partner of which is Baker Brothers Life Sciences Capital, L.P., a limited partnership the
sole general partner of which is Baker Brothers Life Sciences Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling
members of Baker Brothers Life Sciences Capital (GP), LLC.

Certain securities of the Issuer are held directly by 14159,
a limited partnership the sole general partner of which is 14159 Capital, L.P., a limited partnership the sole general partner
of which is 14159 Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling members of 14159 Capital (GP), LLC.

(e) Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: March 28, 2017

	BAKER BROS. ADVISORS LP
	By:  Baker Bros. Advisors (GP) LLC, its general partner
	By:	/s/ Scott L. Lessing
		Name: Scott L. Lessing Title:   President

	BAKER BROS. ADVISORS (GP) LLC
	By:	/s/ Scott L. Lessing
		Name: Scott L. Lessing Title:   President

	/s/ Julian C. Baker
	Julian C. Baker
	/s/ Felix J. Baker
	Felix J. Baker